Dean of the Hebrew University- Hadassah School of Medicine
Director, Center for Research,
Prevention and Treatment of Atherosclerosis
Professor of Medicine
Dorothy & Maurice Bucksbaum Chair in
Molecular Genetics
Hadassah University Hospital, Jerusalem.
Tel: 972-2-6778599
Fax: 972-2-6411136.
E-mail: eranl@hadassah.org.il
Date of birth: 27.10.1950
Marital status: Married and a father of five children (Yoav, Dannah, Yoni, Dean and Orian)
Education
1964-68 Secondary Education, Tel Aviv, Israel.
1968-74 Medical School, Hebrew University-Hadassah Medical School, Jerusalem.
Post Graduate Training
1974-75 Rotating Internship, Hadassah University Hospital, Jerusalem.
1979-84 Medical Residency, Department of Internal Medicine B, Hadassah, University Hospital, Jerusalem, under Prof. Yechezkiel Stein.
1986-88 Research Fellowship, the laboratory of M.S. Brown and J.L. Goldstein, University of Texas, Southwestern Medical Center at Dallas, Texas, U.S.A.
1992 - Visiting Professor, the laboratory of A. Motulsky and S. Deeb, George Washington University, Seattle, Washington, U.S.A.
1995-96 Visiting professor, the laboratory of J.-C Fruchart, Institute Pasteur, Lille, France.
2005-06 Invited Professor, the laboratory of D. Hayoz, Department of Vascualr Medicine, CHUV hospital, Lausanne, Switzerland.
Army Service
1976-80 Flight Surgeon (rank of a Major), Aviation Medicine, Israeli Air Force.
Medical Licenses
1976 - Israel Medical License No. 11957 (General Medicine).
1985 - Israel Medical License No. 8341 (Board Certified in Internal Medicine).
1974 - US Educational Certificate: ECFMG, No. 222-365-9.
Academic Degrees
1975 - M.D., Hebrew University-Hadassah Medical School, Jerusalem.
1981-85 Instructor of Medicine, Faculty of Medicine, Hebrew University.
1985-87 Lecturer of Medicine, Faculty of Medicine, Hebrew University.
1987-92 Senior Lecturer of Medicine, Faculty of Medicine, Hebrew University.
1992-94 Associate Professor of Medicine, Faculty of Medicine, Hebrew University.
1994 - Professor of Medicine, Faculty of Medicine, Hebrew University.
1997 - Dorothy and Maurice Bucksbaum Chair in Molecular Genetics, Hebrew University.
Administrative Experience
1991-93 Director, Metabolic Defects Unit, Department of Medicine B, Hadassah University Hospital, Jerusalem.
Head Ward A, Director, Center for Research, Prevention and Treatment of Atherosclerosis, Division of Medicine, Hadassah University Hospital, Jerusalem.
1997-98 Director, GIS-Genetics, Institute Pasteur, Lille, France.
1997-00 Chairman, Research Committee, Division of Medicine, Hadassah University Hospital, Jerusalem. Director, Center for Research, Prevention and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem.
2001 - Chairman, Department of Medicine B, Hadassah University Hospital, Jerusalem.
Administrative Experience at the Hebrew University - Faculty of Medicine and the Hadassah Medical School
1989-91 Member, the Admission Committee
1989-91 Chairman, Examination Committee, Internal Medicine
1994-97 Member, The Research Committee Internal Medicine
1997-99 Member, The Committee of Planning and Development
1999-00 Member, The Medical Appointment and Promotion Committee
2000-05 Chairman, , The Medical Appointment and Promotion Committee, The Faculty of Medicine and The Faculty of Dentistry, The Hebrew University of Jerusalem
Awards
Since August 2009 – Dean of the Faculty of Medicine, Hebrew University-Hadassah School of Medicine
Hebrew University- Hadassah Medical School, Faculty Prizes
Doljanski Prize: 1976 ‑ Best M.D. Thesis of the Year.
Goldberg Prize: 1983 ‑ Clinical Pathological Correlations in Prosthetic Valve Endocarditis.
Shefer Prize: 1984 ‑ Synthesis & Secretion of Triacylglycerol Lipase by Cultured Rat Hepatocytes.
Goldberg Prize: 1986 ‑ Analysis of Risk Factors in Survivors of Myocardial Infarction.
Halperin Prize:
1990 - Best Clinical Lecturer of The Year.
1992 - Distinguished Clinical Lecturer.
1999 - Distinguished Clinical Lecturer.
International Fellowship Awards
National Institutes of Health (NIH) ‑ Research Fellowship Award (Fogarty), 1986, 1987.
International Atherosclerosis Society (IAS) - Research Fellowship Award, 1992.
Research Grants
Competitive Grants
1988-91 US-Israel Binational Science Foundation, CTX, 27-Hydroxylase
1990-91 Chief Scientist Israel Ministry of Health, FH in Arab families
1993-94 Verum – Germany, LDL oxidation
1993-95 Bundesmi. für Forschung und Technologie, Lp(a) genotyping in FH
1993-97 Israel Academy of Sciences and Humanities, FH in Jewish families
1997-98 Hadassah Hebrew University , Gene Therapy - CYP27
1998-00 German Israeli Foundation for Scientific, CYP27 knockout mouse and Research and Development, atherosclerosis
1998-00 NIH – Subcontract. Genetics of Sudden Death
1998-02 Israel Academy of Sciences and Humanities. CYP27 overexpressing mouse
1998-01 Chief Scientist Israel Ministry of Health. Genetics of cardiomyopathy
2000-01 Hadasit. LDL lowering gene
2000-04 Israel Academy of Sciences and Humanities. LRC project
Industry-supported Research Grants
1989-96 Sandoz Pharma Ltd., Basel Switzerland. Fluvastatin in FH
1993-96 Merck and Co. (through Assia Riesel Ltd.) MED PED FH research
1997-00 Novartis Pharma AG, Basel Switzerland. Fluvastatin in FH
1997-00 MSD - Israel . MED PED FH research
1997-98 MSD - Israel . Simvastatin-Atorvastatin trial
1997-99 MSD – Israel. FH-Express Trial
1998-99 Merck & Co. - University Program. LDL-R in FH families
1998-00 MSD - Israel . Holem Study
1999-00 Astra-Zeneca. FH studies (HTZ and HMZ)
1999-00 Negma-Kowa. Combined hyperlipidemia
2000-03 Schering-Plough. Ezetimibe in Homozygote FH
2004-05 MRL. MTP inhibitor in Homozygote FH
2004-05 MRL. MTP inhibitor in Type V hyperlipidemia
2004-06 Sankyo. ACAT inhibitor in FH
2006 Sankyo. Pediatric FH Study
2006 Kowa. Hyperlipidemia in elderly patients
2006 Takeda. TAK475 in subject with primary Hypercholesterolemia
Private Donations for Research
1993 Suria Kupty Research Foundation. Gene bank
1994-95 Sara Cohen Research Foundation. Diet and Genes
1991-06 Sarah Mayer Research Foundation. FH research
Administrative positions in Multicenter International Studies
1998-05 TNT study. Worldwidem Data Safety & Monitoring Board Member
1999-00 FAME study. France, Italy, Spain, Belgium and Israel. Steering Committee Member
Organization of International Meetings
1991 International Atherosclerosis Society, Chicago, USA, Member, organizing IXth International Symposium Committee on Atherosclerosis
1993 European Atherosclerosis Society, Jerusalem, Israel. Scientific Secretary 62nd EAS Congress.
1998 European Atherosclerosis Society, Geneva, Switzerland. Scientific Secretary 70th EAS Congress
Organization of National Annual Meetings
1995 Israeli Atherosclerosis Society, Eilat, Israel. Secretary
1996 Israeli Atherosclerosis Society, Eilat, Israel. Secretary
1997 Israeli Atherosclerosis Society, Eilat, Israel. Secretary
1998 Israeli Atherosclerosis Society, Eilat, Israel. Secretary
1999 Israeli Atherosclerosis Society, Eilat, Israel. Secretary
2000 Israeli Atherosclerosis Society, Eilat, Israel. Chairman
2001 Israeli Atherosclerosis Society, Eilat, Israel. Chairman
2002 Israeli Atherosclerosis Society, Eilat, Israel. Chairman
2003 Israeli Atherosclerosis Society, Eilat, Israel. Organizer
Scientific Organizations
1995 Israel Academy of Sciences and Humanities, Member of the Committee for Experimental Medicine
1998-00 Israel Academy of Sciences and Humanities, Chairman of the Committee for Experimental Medicine
1975 Israel Medical Society, Member
1997Israel Heart Society, Member
1994-9 Israel Society for Research, Prevention and Treatment of Atherosclerosis, Secretary
1999 Israel Society for Research, Prevention and Treatment of Atherosclerosis, Chairman
1996 American Heart Association Council on Atherosclerosis, Member
1999 Mediterranean Society for Atherosclerosis, Member of the Executive Committee
1994 European Atherosclerosis Society, Member
1994 International Atherosclerosis Society, Member
1988 American Society of Human Genetics, Member
Reviewer for National Organizations
§ The Israel Ministry of Health
§ US-Israel Binational Science Foundation
§ Israel Academy of Sciences and Humanities
§ German Israeli Foundation for Scientific Research and Development
§ The Austrian National Science Foundation (FWF)
§ The Swiss National Science Foundation
§ The Netherlands Organization for Scientific Research (NWO)
§ The German Human Genome Project (GHGP)
§ The Welcome Trust (UK)
Reviewer for Scientific Journals
§ American Journal of Human Genetics
§ Human Genetics
§ Clinical Genetics
§ Journal of Clinical Investigation
§ Arteriosclerosis Thrombosis and Vascular Biology
§ Atherosclerosis
§ Israel Journal of Medical Science
§ Journal of Vascular Research
§ European Journal of Clinical Investigation
§ Human Molecular Genetics
§ Genetic Epidemiology
§ Circulation
Member of Editorial Board
§ Atherosclerosis (since 1998)
§ Arteriosclerosis, Thrombosis, and Vascular Biology (since 2001)
§ Nutrition Metabolism and Cardiovascular Disease (since 2002)
LIST OF PUBLICATIONS
Original Articles
Brautbar N, Levi J, Rosler A, Leitersdorf E, Djaldeti M, Epstein M, Kleeman CR (1978) Familial hyperkalemia, hypertension and hyporeninemia with normal aldosterone levels. A tubular defect in potassium handling. Arch Int Med 138:607‑610.
Zeimer R, Belkin M, Leitersdorf E, Rachmilewitz EA (1978) A non‑invasive method for evaluation of tissue iron deposition in beta thalassemia major. J Lab Clin Med 91:24‑31.
Charnilas J, Leitersdorf E, Barbash G (1979) Evaluation of the helicopter in aeromedical transfer. Aviation Space and Environmental Medicine 50:846.
Leitersdorf E, Friedman G, Gozal D, Appelbaum A, Sacks T, Levi IJ (1982) Hypothesis: New concepts on the pathogenesis of early prosthetic valve endocarditis. Medical Hypothesis 9:325‑330.
Leitersdorf E, Goshen R, Shefer A (1982) Atypical ventricular tachycardia in combined tetracyclic antidepressant neuroleptic and anticholinergic drugs interaction. Int’l J Psych In Med 12(2):85‑91.
Leitersdorf E, Friedman G, Gozal D, Appelbaum A, Sacks T (1983) Infective endocarditis in Jerusalem. A comparative analysis of native and prosthetic valve endocarditis. Isr J Med Sci 19:491‑494.
Stein Y, Halperin G, Leitersdorf E, Dabach Y, Hollander G, Stein O (1984) Metabolism of liposomes prepared from a labeled ether analog of 1,2- dioleoyl‑sn‑glycero‑3‑phosphocholine in the rat. Biochim Biophys Acta 793:354‑364.
Leitersdorf E, Stein O, Stein Y (1984) Synthesis and secretion of triacylglycerol lipase by cultured rat hepatocytes. Biochim Biophys Acta 794:261‑268.
Raz I, Koffler M, Leitersdorf E, Bar‑On H (1984) Maintenance of ambulatory diabetic patients on subcutaneous insulin pump. Isr J Med Sci 20:731‑735.
Stein O, Halperin E, Leitersdorf E, Olivecrona T, Stein Y (1984) Lipoprotein lipase mediated uptake of non‑degradable ether analogues of phosphatidylcholine and cholesteryl ester by cultured cells. Biochim Biophys Acta 795:47‑59.
Leitersdorf E, Stein O, Eisenberg S, Stein Y (1984) Uptake of rat plasma HDL subfractions labeled with [3H]cholesteryl linoleyl ether or with 125I by cultured rat hepatocytes and adrenal cells. Biochim Biophys Acta 796:72‑82.
Shinar E, Leitersdorf E, Yevin R (1984) Lactobacillus plantarum endocarditis. Klin Wochenschr 62:1173‑1174
Leitersdorf E, Israeli A, Raz I (1984) Anorexia nervosa - an unusual presentation of the Plummer – Vinson Syndrome. Int’l J Psych Med 14:343-346.
Stein O, Leitersdorf E, Stein Y (1985) Verapamil enhances receptor mediated endocytosis of low density lipoproteins by aortic cells in culture. Arteriosclerosis 5:35‑44.
Israeli A, Or R, Leitersdorf E, (1985) Captopril associated transient aplastic anemia. Acta Haemat 73:106‑107.
Raz I, Leitersdorf E, Kleinman Y (1985) Acute bilateral brachial plexus neuritis associated with hypersensitivity vasculitis. A case report and review of literature. Klin Wochenschr 63:643‑645.
Gillis DJ, Wengrower D, Witztum E Leitersdorf E (1985) Fenfluramine and Mazindol: Acute Reversible cardiomyopathy associated with their use. Int’l J Psych In Med 15(2):197‑200.
Leitersdorf E, Stein O, Stein Y (1985) Angiotensin II stimulates receptor mediated uptake of LDL by bovine adrenal cortical cells in primary culture. Biochim Biophys Acta 835:183‑190.
Drenger B, Israeli A, Or R, Leitersdorf E (1985) Plasmapheresis for streptococcal sepsis? The Lancet ii(2):943.
Leitersdorf E, Gottehrer N, Fainaru M, Friedlander Y, Friedman G, Tzivoni D, Stein Y (1986) Analysis of risk factors in 532 survivors of first myocardial infarction hospitalized in Jerusalem. Atherosclerosis 59:75‑93.
Admon D, Gottehrer N, Leitersdorf E (1986) Is “primary” subphrenic abscess caused by streptococcus milleri ‑ a result of unrecognized gastrointestinal perforation? Klin Wochenschr 64:287‑289.
Raveh D, Wengrower D, Kleinman J, Leitersdorf E (1986) Triethylene Tetramine in Wilson’s disease. Harefuah 110:178‑179 (in Hebrew).
Drenger B, Zidenbaum M, Reifen E, Leitersdorf E (1986) Severe upper airway obstruction and difficult intubation in cicatricial pemphigoid. Anaesthesia 41:1029‑1031.
Wengrower D, Tsfoni EE, Drenger B, Leitersdorf E (1986) Erythroderma and pneumonitis induced by penicillin. Respiration 50:301‑303.
Leitersdorf E, Israeli A, Stein O, Eisenberg S, Stein Y (1986) The role of apolipoproteins of HDL in the selective uptake of cholesteryl linoleyl ether by cultured rat and bovine adrenal cells. Biochim Biophys Acta 878:320‑329.
Klapholz L, Leitersdorf E, Weinrauch L (1986) Leukocytoclastic vasculitis and pneumonitis induced by Metformin. Brit Med J 293:483.
Israeli A, Or R, Leitersdorf E (1986) Captopril associated transient aplastic anemia. Toxicology Abstracts 9:28.
Stein O, Israeli A, Leitersdorf E, Halperin G, Stein Y (1986) Preferential uptake of cholesteryl ester‑HDL by cultured macrophages. Atherosclerosis 75:151‑158.
Gavish D, Eisenberg S, Berry EM, Kleinman Y, Witztum E, Norman J, Leitersdorf E (1987) Bulimia ‑ an underlying behavioral disorder in hyperlipidemic pancreatitis. A prospective multidisciplinary approach. Arch Int Med 147:705‑708.
Israeli A, Leitersdorf E, Stein O, Stein Y (1987) Preferential binding of [3H]cholesteryl linoleyl ether-HDL3 by bovine adrenal membranes. Biochim Biophys Acta 902:128‑132.
Leitersdorf E, Hobbs HH (1987) Human LDL receptor gene: Two ApaLI RFLPs. Nuc Acids Res 15:2782.
Levy‑Lahad E, Steiner‑Salz D, Berkman N, Chisin R, Levensart P, Leitersdorf E (1987) Reversible functional asplenia and subcapsular liver hematoma ‑ two distinctive manifestations of amyloidosis. Klin Wochenschr 65:1104‑1107.
Hobbs H, Leitersdorf E, Goldstein JL, Brown MS, Russell DW (1988) Multiple CRM‑ mutations in familial hypercholesterolemia: Evidence for 13 alleles, including four deletions. J Clin Invest 81:909-917.
Leitersdorf E, Hobbs H (1988) Human LDL receptor gene: HincII polymorphism detected by gene amplification. Nuc Acids Res 16:7215.
Leitersdorf E, Hobbs H, Fourie AM, Jacobs M, van der Westhuyzen DR, Coetzee GA (1988) Deletion in first cysteine‑rich repeat of low density lipoprotein receptor impairs its transport but not lipoprotein binding in fibroblasts from a subject with familial hypercholesterolemia. Proc Natl Acad Sci USA 85:7912‑7916.
Leitersdorf E, Chakravarti A, Hobbs HH (1989) Polymorphic DNA haplotypes at the LDL receptor locus. Am J Hum Genetics 44:409‑421.
Hobbs HH, Leitersdorf E, Calloway C, Cryer DR, Brown MS, Goldstein JL (1989) Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective LDL receptors. J Clin Invest 84:656‑664,
Leitersdorf E, van der Westhuyzen DR, Coetzee GA Hobbs HH (1989) Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners. J Clin Invest 84:954‑961.
Leitersdorf E, Banai Y, Friedman G, Kaempfer R (1989) Superinduction of the human gene encoding low density lipoprotein receptor. Biochem Biophys Res Commun 165(2):574-580.
Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH (1990) Common low density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 85:1014-1023.
Leitersdorf E, Luskey KL (1990) HgiAI polymorphism near the HMGCR promoter. Nuc Acids Res 18:5584.
Leitersdorf E, Hwang M, Luskey KL (1990) ScrFI polymorphism in the 2nd intron of the HMGCR gene. Nuc Acids Res 18:5584.
Stein O, Stein Y, Pressman Schwartz S, Reshef A, Chajek-Shaul T, Ben-Naim M, Friedman G, Leitersdorf E (1991) Expression of lipoprotein lipase mRNA in rat heart is localized mainly to mesenchymal cells as studied by in-situ hybridization. Arteriosclerosis and Thrombosis 11:857-863
Meiner V, Landsberger D, Berkman N, Reshef A, Segal P, Seftel HC, van der Westhuyzen DR, Jeenah MS, Coetzee GA, Leitersdorf E (1991) A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. Am J Hum Genet 49:443-449.
Oppenheim AY, Friedlander Y, Dann EJ, Berkman N, Pressman Schwartz S, Leitersdorf E (1991) Hypercholesterolemia in five Israeli Christian-Arab kindreds is caused by the “Lebanese” allele at the LDL receptor gene locus and by an additional independent major factor. Hum Genetics 88:75-84.
Leitersdorf E, Friedlander Y, Bard JM, Fruchart JC, Eisenberg S, Stein Y (1991) Diverse effect of ethnicity on plasma lipoprotein(a) levels in heterozygote patients with familial hypercholesterolemia. J Lipid Res 32:1513-1519.
Berkman N, Weir BS, Pressman Schwartz S, Reshef A, Leitersdorf E (1992) Haplotype analysis at the low density lipoprotein receptor locus: application to the study of familial hypercholesterolemia in Israel. Hum Genetics 88:405-410.
Landsberger D, Meiner V, Reshef A, Levy Y, van der Westhuyzen DR, Coetzee GA, Leitersdorf E (1992) A nonsense mutation in the LDL receptor gene leads to familial hypercholesterolemia in the Druze sect. Am J Hum Genet 50:427-433.
Reshef A, Meiner V, Dann EJ, Granat M, Leitersdorf E (1992) Prenatal diagnosis of familial hypercholesterolemia caused by the “Lebanese” mutation at the LDL receptor gene locus. Hum Genetics 89:237-239.
Friedman G, Reshef A, Ben-Naim M, Leitersdorf E, Stein O, Stein Y (1992) Regulation of lipoprotein lipase by dibutyryl cAMP, cholera toxin, Hepes and heparin in F1 heart-cell cultures. Biochim Biophys Acta 1137:237-241.
Rubinsztein DC, Coetzee GA, Marais AD, Leitersdorf E, Seftel HC, van der Westhuyzen DR (1992) Identification and properties of the proline664-leucine mutant LDL receptor in South Africans of Indian origin. J Lipid Res 33:1647-1655.
Friedlander Y, Dann EJ, Leitersdorf E (1993) Absence of familial defective apolipoprotein B-100 in Israeli patients with dominantly inherited hypercholesterolemia and in offspring with parental history of myocardial infarction. Hum Genet 91:299-300.
Leitersdorf E, Reshef A, Meiner V, Dann EJ, Beigel Y, van Roggen FG, van der Westhuyzen DR, Coetzee GA (1993) A missense mutation in the low density lipoprotein receptor gene causes familial hypercholesterolemia in Sephardic Jews. Hum Genetics 91:141-147.
Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M, Bard JM, Fruchart JC, Stein Y (1993) Genetic Determinants of responsiveness to the HMG CoA reductase inhibitor fluvastatin in patients with molecularly defined familial hypercholesterolemia. Circulation 87 [suppl III]:III-35-III-44.
Leitersdorf E, Reshef A, Meiner V, Levitzki R, Pressman Schwartz S, Dann EJ, Berkman N, Cali JJ, Klapholz L, Berginer VM (1993) Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews of Moroccan origin. J Clin Invest 91:2488-2496.
Rubinsztein DC, Jialal I, Leitersdorf E, Coetzee GA, van der Westhuyzen DR (1993) Identification of 2 new LDL-receptor mutations causing homozygous familial hypercholesterolemia in a South African of Indian origin. Biochim Biophys Acta 1182: 75-82.
Leitersdorf E, Eisenberg S, Eliav O, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Peters TK, Muratti EN, Bard JM, Fruchart JC, Stein Y (1993) Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolemia. European J Clin Pharmacol 45:513-518.
Meiner V Marais DA, Reshef A, Bjorkhem I, Leitersdorf E (1994) Premature termination codon at the Sterol 27-hydroxylase gene causes cerebrotendinous xanthomatosis in an Afrikaner family. Hum Mol Genet 3:193-194.
Reshef A, Meiner V, Berginer VM, Leitersdorf E (1994) Molecular genetics of cerebrotendinous xanthomatosis in Jews of North African origin. J Lipid Res 35:478-483.
Meiner V., Meiner Z, Reshef A, Marais DA, Bjorkhem I, Leitersdorf E (1994) Cerebrotendinous xanthomatosis: Molecular diagnosis enables pre-symptomatic detection of a treatable disease. Neurology 44:288-290.
Leitersdorf E (1994) Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia. Drugs, 47 (Supp 2): 54-58.
Leitersdorf E, Muratti EN, Eliav O, Meiner V, Eisenberg S, Dann EJ, Sehayek E, Peters TK, Stein Y (1994) Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: Comparative analysis to a fluvastatin-cholestyramine combination. Am J Med 96:401-407.
Muratti EN, Peters TK, Leitersdorf E (1994) Fluvastatin in familial hypercholesterolemia: A cohort analysis of the response to combination treatment. Am J Cardiol 73:30D-38D.
Leitersdorf E, Safadi R, Meiner V, Reshef A, Bjorkhem I, Friedlander Y, Morkos S, Berginer VM (1994) Cerebrotendinous xanthomatosis in the Israeli Druze: molecular genetics and phenotypic characteristics. Am J Hum Genet 55:907-915.
Segev H, Reshef A, Clavey V, Delbart C, Routier G, Leitersdorf E (1995) Premature termination codon at the sterol 27-hydroxylase gene causes cerebrotendinous xanthomatosis in a French family. Hum Genet 95:238-240.
Friedlander Y, Berry EM, Eisenberg S, Stein Y, Leitersdorf E (1995) Plasma lipids and lipoproteins response to a dietary challenge: analysis of four candidate genes. Clin Genet 47:1-12.
Friedlander Y, Leitersdorf E (1995) Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia. Genetic Epidem 12:129-143.
Eliav O, Schurr D, Pfister P, Friedlander Y, Leitersdorf E (1995) High dose fluvastatin and bezafibrate combination treatment of patients with heterozygous familial hypercholesterolemia. Am J Cardiol 76:76A-79A.
Leitersdorf E, Muratti EN, Eliav O, Peters TK (1995) Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for patients with severe familial hypercholesterolemia: a cohort analysis. Am J Cardiol 76:84A-88A.
Watts GF, Mitchell WD, Bending JJ, Reshef A, Leitersdorf E (1996) Cerebrotendinous Xanthomatosis in an English family: clinical characteristics, molecular genetics and pharmacotherapy. Quat J Med, 89:55-63.
Friedlander Y, Leitersdorf E (1996). Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: results from a segregation analysis in pedigrees with molecularly defined familial hypercholesterolemia. Genetic Epidem 13:159-177.
Dann J, Friedlander Y, Leitersdorf E, Nagler A (1996) The modulation of plasma lipids and lipoproteins during bone marrow transplantation is unrelated to exogenously administered recombinant human granulocyte monocyte colony stimulating factor (RHU GM CSF). Medical Oncology 13:81-86.
Reshef A, Nissen H, Triger L, Hensen TS, Eliav O, Schurr D, Safadi R, Gare M, Leitersdorf E (1996) Molecular genetics of familial hypercholesterolemia in Israel. Human Genetics 98:581-586.
Assouline L, Leitersdorf E, Lambert M, Reshef A, Feoli-Fonseca JC, Levy E (1997) Identification of two novel LDL receptor gene defects in French Canadian pediatric population: mutational analysis and biochemical studies. Human Mutation 9:555-562.
Babiker A, Andersson O, Lund E, Xiu RJ, Deeb S, Reshef A, Leitersdorf E, Diczfalusy U, Bjorkhem J (1997) Elimination of cholesterol in macrophages and endothelial cells by the sterol 27 hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem 272:26253-26261.
Rosen H, Reshef A, Maeda N, Lippoldt A, Shpizen S, Triger L, Eggertsen G, Björkhem I and Leitersdorf E (1998) Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J Biol Chem 273:14805-14812.
Sviri S, Shpizen S, Leitersdorf E, Levy M, Caraco Y (1999) Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Therap 65:275-282.
Martinez-Botas J, Surez Y, Reshef A, Carrero P, Ortega H, Gomez-Coronado D, Luis Teruel J, Leitersdorf E, Lasuncion MA (1999) Impact of different LDL-receptor mutations on the ability of LDL to support lymphocyte proliferation. Metabolism. 48:834-839.
Gervois P, Torra IP, Chinetti G, Grotzinger T, Dubois G, Fruchart JC, Fruchart-Najib J, Leitersdorf E, Staels B (1999) A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol Endocrinol 13:1535-1549.
Knoblauch H, Müller-Myhsok B, Busjahn A, Ben Avi L, Bähring S, Baron H, Heath SC, Uhlmann R, Faulhaber HD, Shpitzen S, Aydin A, Reshef A, Rosenthal M, Eliav O, Mühl A, Lowe A, Schurr D, Harats D, Jeschke E, Friedlander Y, Schuster H, Luft FC, Leitersdorf E (2000) A Cholesterol-lowering gene maps to chromosome 13q. Am J Hum Genet 66:157-166.
Kark JD, Sinnreich R, Leitersdorf E, Friedlander Y, Shpitzen S, Luc G (2000) Taq 1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol. Atherosclerosis 151:509-518. .
Halperin G, Elisaf M, Leitersdorf E, Harats D (2000) A new method for determination of serum cholestanol by high performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci 742:345-352.
Higazi AA, Nassar T, Ganz T, Rader DJ, Udassin R, Bdeir K, Hiss E, Sachais BS, Williams KJ, Leitersdorf E, Cines DB (2000) The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflamatory apolipoprotein and a possible contributor to atherogenesis. Blood 96:1393-1398.
Friedlander Y, Leitersdorf E, Vecsler R, Funke H, Kark J (2000) The contribution of candidate genes to the response of plasma lipids and lipoproteins to dietary challenge. Atherosclerosis 152:239-248.
Repa JJ, Lund EG, Horton JD, Leitersdorf E, Russell DW, Dietschy JM, Turley SD (2000) Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia: reversal by cholic acid feeding. J Biol Chem 275:39685-39692.
Honda A, Salen G, Matsuzaki Y, Batta AK, Xu G, Leitersdorf E, Erickson SK, Tanaka N, Shefer S (2001) Differences in hepatic levels of intermediates in bile acid biosynthesis between CYP27(-/-) mice and CTX. J Lipid Res 42:291-300.
Burnett JR, Moses EA, Croft KD, Brown AJ, Grainger K, Vasikaran SD, Leitersdorf E, Watts GF (2001) Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clin Chim Acta 306:63-69
Durst R, Colombo R, Shpitzen S, Ben Avi L, Friedlander Y, Wexler R, Raal FJ, Marais DA, Defesche JC, Mandelshtam MY, Kotze MJ, Leitersdorf E, Meiner V(2001) Recent origin and spread of a common Lithuanian mutation (G197del LDLR) causing familial hypercholesterolemia: Positive selection is not always necessary to account for disease incidence among Ashkenazi Jews. Am J Hum Genet 68:1172-1188.
Segev H, Honigman A, Rosen H, Leitersdorf E (2001) Transcriptional regulation of the human sterol 27-hydroxylase gene (CYP27) and promoter mapping. Atherosclerosis 156:339-47.
Honda A, Salen G, Matsuzaki Y, Batta AK, Xu G, Leitersdorf E, Tin GS, Erickson SK, Tanaka N, Shefer S (2001) Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis. J Biol Chem 14:34579-85.
Meiner V, Shpitzen S, Mandel H, Klar A, Ben-Neriah Z, Zlotogora J, Sagi M, Lossos A, Bargal R, Sury V, Carmi R, Leitersdorf E, Zeigler M (2001) Clinical-biochemical correlation in molecularly characterized patients with Niemann-Pick type C. Genet Med 3:343-8.
Miserez AR, Muller PY, Barella L, Barella S, Staehelin HB, Leitersdorf E, Kark JD, Friedlander Y (2002) Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolemia. Atherosclerosis. 164:15-26.
Meir K, Kitsberg D, Alkalay I, Szafer F, Rosen H, Shpitzen S, Ben Avi L, Staels B, Fievet C, Meiner V, Bjorkhem I, Leitersdorf E (2002) Human sterol 27-hydroxylase (Cyp27) overexpressor transgenic mouse model. Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis. J Biol Chem 277:34036-34041.
Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, Hiss E, Zipporen L, Aviram M, Cines DB, Poncz M, Higazi AA (2003) . Platelet factor 4 enhances the binding of oxidized-low density lipoprotein to vascular wall cells. J Biol Chem 278:6187-93.
Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL, Leitersdorf E, Mangelsdorf DJ, Kliewer SA, Repa JJ (2003) Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci U S A 100:223-8.
Bruckert E, Lievre M, Giral P, Crepaldi G, Masana L, Vrolix M, Leitersdorf E, Dejager S. (2003) Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol. 12:225-31.
Cahn A, Meiner V, Leitersdorf E, Berkman N (2004) Identification of a novel mutation in the gene for bone morphogenetic protein receptor II in an Israeli patient with familial primary pulmonary hypertension. Isr Med Assoc J 6:156-9.
Elazary AS, Lador N, Shauer A, Meir K, Pollak A, Wolf DG, Raz I, Leitersdorf E, Mevorach D (2004) Tongue necrosis and pericarditis. Lancet 363:948.
Neumark YD, Friedlander Y, Durst R, Leitersdorf E, Jaffe D, Ramchandani VA, O'Connor S, Carr LG, Li TK (2004) Alcohol dehydrogenase polymorphisms influence alcohol-elimination rates in a male Jewish population. Alcohol Clin Exp Res 28:10-4.
Ben-Avi L, Durst R, Shpitzen S, Leitersdorf E, Meiner V (2004) Aplipoprotein E genotyping: accurate, simple, high throughput method using ABI Prism SNaPshot Multiplex System. J Alzheimers Dis 6:497-501.
Mazal B, Amital H, Barkan D, Shaham D, Leitersdorf E. (2004) Splenic infarction as an unusual cause of left pleural effusion Harefuah 143:563-5.
Karban A, Atia O, Leitersdorf E, Shahbari A, Sbeit W, Ackerman Z, Mualem R, Levine A, Nesher S, Safadi R, Eliakim R. (2005) The relation between NOD2/CARD15 mutations and the prevalence and phenotypic heterogeneity of Crohn's disease: lessons from the Israeli Arab Crohn's disease cohort. Dig Dis Sci 50:1692-7.
Bercovich D, Friedlander Y, Korem S, Houminer A, Hoffman A, Kleinberg L, Shochat C, Leitersdorf E, Meiner V (2006) The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis 185:97-107.
Harats D, Leibovitz E, Maislos M, Wolfovitz E, Chajek-Shaul T, Leitersdorf E, Gavish D, Gerber Y, Goldbourt U; HOLEM Study Group (2005) Cardiovascular risk assessment and treatment to target low density lipoprotein levels in hospitalized ischemic heart disease patients: results of the HOLEM study. Isr Med Assoc J 7:355-9.
Durst R, Jansen A, Erez G, Bravdo R, Butbul E, Ben Avi L, Shpitzen S, Lotan C, Leitersdorf E, Defesche J, Friedlander Y, Meiner V, Miserez AR (2006) The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients. Atherosclerosis. 2006 Feb 6; [Epub ahead of print]
Rami AF, Barkan D, Mevorach D, Leitersdorf E, Caraco Y (2006) Clozapine-induced systemic lupus erythematosus. Ann Pharmacother 40:983-5.
Fanne RA, Khamaisi M, Mevorach D, Leitersdorf E, Berkman N, Laxer U, Maly B (2006) Spontaneous rupture of lung echinococcal cyst causing anaphylactic shock and respiratory distress syndrome. Thorax 61:550.
Khamaisi M, Anner H, Marincheva G, Leitersdorf E, Bogot N (2006) Stent graft in treatment of penetrating thoracic aortic ulcer. J Am Soc Echocardiogr. 19:835.e4-6.
Chapters, Reviews, Commentaries and Editorials
Stein O, Leitersdorf E, Olivecrona T, Stein Y (1986) Separate pathways of endocytosis of lipoprotein components. Proceedings of 7th Int. Symp. Atherosclerosis, Melbourne, Oct.1985, Atherosclerosis Elsevier VII:381‑384.
Stein O, Leitersdorf E, Chajek‑Shaul T, Friedman G, Stein Y (1986) Studies on lipolytic enzymes in cell culture. Monogr Atherosclerosis 14:124‑128.
Leitersdorf E, van der Westhuyzen DR, Coetzee GA (1992) Founder LDL receptor gene mutations lead to familial hypercholesterolemia in Israel. Atherosclerosis IX: Proceedings of the Ninth International Symposium on Atherosclerosis. Ed. Stein O, Eisenberg S, Stein Y. R&L Creative Communications Ltd. pp 149-151.
Leitersdorf E (1992) Genetic heterogeneity of LDL receptor gene mutations in diverse ethnic groups, genotypic-phenotypic correlations and pharmacogenetics. Nutrition Metab Cardiovasc Dis (Editorial) 2:1-2.
Meiner V, Leitersdorf E (1993) Lipoprotein (a): a risk factor for atherosclerosis. Harefuah 123:115-118.
Leitersdorf E, Meiner V (1994) Cerebrotendinous xanthomatosis. Curr Opinion Lipidology 5:138-142.
Leitersdorf E (1994) Familial hypercholesterolemia. Genetic factors in coronary heart disease. Ed. Goldbourt U, Faire U, Berg K. Kluwer Academic Publications pp 267-273.
Leitersdorf E (1994) The patient at risk: who should we be treating? Brit J Clin Prac, 77 (sup):24-27.
Caspi O, Leitersdorf E (1995) Can regression of coronary atherosclerosis be induced? Harefuah 128:290-295.
Shviro I, Leitersdorf E (1995) Impact of hormone replacement therapy on the cardiovascular system. Harefuah 128:561-566.
Leitersdorf E, Reshef A (1995) Molecular heterogeneity of familial hypercholesterolemia in the Arab communities in Israel. Atherosclerosis X: Proceedings of the Tenth International Symposium on Atherosclerosis. Ed. Woodford FP, Davignon J, Sniderman A. Elsevier Science BV. pp 447-450.
Leitersdorf E, Stein Y (1995) Obituary: Shlomo Eisenberg, 1935-1995. Atherosclerosis 114:255.
Shviro I, Leitersdorf E (1995) Postmenopausal hormone replacement therapy for the prevention of coronary artery disease. Cardiol Update 11:17-19.
Leitersdorf I, Leitersdorf E (1995) Molecular genetics of hypertrophic cardiomyopathy and its clinical implications. Cardiol Update 16:15-17.
Williams RR, Hamilton-Craig I, Kostner GM, Hegele RA, Hayden MR, Pimstone SN, Faergeman O, Schuster H, Steinhagen-Thiessen E, Beisiegel U, Keller C, Czeizel A, Leitersdorf E, Kastelein JC, Defesche JJP, Ose L, Leren T, Seftel HC, Raal FJ, Marais AD, Eriksson M, Keller U, Miserez A, Jeck T, Betteridge DJ, Humphries SE, Day INM, Kwiterovich PO, Lees RS, Stein E, Illingworth R, Kane J, Boulyjenkov V (1996) MED PED: an integrated genetic strategy for preventing early deaths. Genetic approaches to non communicable diseases; Springer Verlag, Berlin Heidelberg.
Shviro I, Leitersdorf E (1996) The patient at risk: who should we be treating? Brit J Clin Prac 77A:24-27.
Leitersdorf E (1996) Control of lipoprotein levels in coronary heart disease today: a focus on high-dose fluvastatin and combination therapies. Drugs affecting lipid metabolism, risk factors and future directions. Ed. Gotto AM, Paoletti R, Smith LC, Catapano AL, Jackson AS. Kluwer Academic Publishers. pp 567-570.
Shviro I, Leitersdorf E (1996) Postmenopausal hormone replacement therapy for the prevention of coronary artery disease. Internal Med Update 10:27-30.
Shviro I, Leitersdorf E (1996) Targeted prevention of coronary heart disease: pharmacological considerations in multi-modality treatment. Cardiology 87:469-475.
Leitersdorf E (1997) Preventing coronary heart disease: closing the loop. In: Vascular Disease in the Older Person. The Parthenon Publishing Group pp 101-104.
Fruchart JC, Brewer HB, Leitersdorf E (1998) Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol, 81:912-917.
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093.
Björkhem I, Leitersdorf E (2000) Sterol 27-hydroxylase deficiency: A rare cause of xanthomas in normocholesterolemic humans. Trends Endocrinol Metab 11:180-183.
Meiner V, Leitersdorf E (2000) Cerebrotendinous xanthomatosis. In: Neurological Ataxia, Marcel Dekker/Klockgether publishers. pp 257-269.
Björkhem I, Boberg KM, Leitersdorf E (2001) Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW and Vogelstein B. The Metabolic and Molecular Bases of Inherited Disease, 8th ed., New York, McGraw-Hill, pp 2961-2988.
Lievre M, Menard J, Buckert E, Cogneau J, Delahaye F, Giral P, Leitersdorf E, Luc G, Masana L, Moulin P, Passa P, Pouchain D, Siest G (2001) Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. British Medical J 322:603-606.
Leitersdorf E (2001) Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management. Eur Heart J 3:E17-E23.
Meir K, Leitersdorf E, Hennekens CH (2001) Inflammation in atherosclerosis - causal or casual? The need for randomized trials of anti-inflammatory agents http://www.athero.org/comm06.html
Leitersdorf E (2002) Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Intern J Clin Pract, 56:116-119.
Durst R, Rund R, Schurr D, Eliav O, Ben-Yehuda D, Shpizen S, Ben-Avi L, Schaap T, Pelz F, Leiterdorf E (2002) One year experience with an LDL apheresis system. Israel Med Asso J 4:677-80.
Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. (2003) Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163:553-64
Meir K, Leitersdorf E, Hennekens CH (2003) Inflammation in atherosclerosis - causal or casual? The need for randomized trials. Am Heart J 146:199-202.
Meir KS, Leitersdorf E (2004) Atherosclerosis in the apolipoprotein E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 24:1006-14.
More in PubMed